InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently hired a Contract Research Organization (“CRO”) for its third human pilot study. “This marks a milestone for the company, notably since it announced its focus solely on glucagon-like peptide 1 (‘GLP-1’) studies for the 2024 calendar year… This randomized, crossover investigation will evaluate a dual-action GLP-1 + glucose-dependent insulintropic peptide (‘GIP’), specifically…